CA9
Carbonic anhydrase 9
As of the edition of 20 October 2026, CA9 (carbonic anhydrase 9, UniProt Q16790) has 4 drugs tested at it and 3 companies on the list, 1 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q16790
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 32
- Disease areas
- Cancer; Pregnancy and women's health; Urinary and reproductive
- Registered trials of its drugs
- 15
Drugs at this target
| Status | Count |
|---|---|
| Active | 1 |
| Stopped | 3 |
| Total | 4 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Girentuximab | Active | Phase 3 | none listed |
| Iodine i 124 girentuximab | Stopped | Phase 3 | none listed |
| SLC-0111 | Stopped | Phase 2 | none listed |
| DTP-348 | Stopped | Phase 1 | none listed |
4 of 4 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Engaged | 2 |
| Total on the list | 3 |
| Company | Route |
|---|---|
| Welichem Biotech | Route A |
The other 2 companies at CA9
In the product3 companies in all; 2 are not named here, and no score is.
See the 3 companies at CA9, ranked, with the facts behind eachRequest access. Nothing is shown until you do.